Argenica Therapeutics Ltd - Asset Resilience Ratio

Latest as of June 2023: 0.52%

Argenica Therapeutics Ltd (AGN) has an Asset Resilience Ratio of 0.52% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Argenica Therapeutics Ltd financial flexibility index to measure the company's free cash flow as a share of total liabilities.

Liquid Assets

AU$50.00K

≈ $35.38K USD Cash + Short-term Investments

Total Assets

AU$9.54 Million

≈ $6.75 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2022–2022)

This chart shows how Argenica Therapeutics Ltd's Asset Resilience Ratio has changed over time. See Argenica Therapeutics Ltd balance sheet quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Argenica Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AGN market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$0.00	0%
Short-term Investments	AU$50.00K	0.52%
Total Liquid Assets	AU$50.00K	0.52%

Asset Resilience Insights

Limited Liquidity: Argenica Therapeutics Ltd maintains only 0.52% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Argenica Therapeutics Ltd Industry Peers by Asset Resilience Ratio

Compare Argenica Therapeutics Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Revolution Medicines Inc NASDAQ:RVMD	Biotechnology	65.10%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Hugel Inc KQ:145020	Biotechnology	29.57%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	Biotechnology	39.07%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A SHG:688076	Biotechnology	2.30%
Absci Corp NASDAQ:ABSI	Biotechnology	59.86%
Shenzhen Weiguang Biological Products Co Ltd SHE:002880	Biotechnology	5.52%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%

Annual Asset Resilience Ratio for Argenica Therapeutics Ltd (2022–2022)

The table below shows the annual Asset Resilience Ratio data for Argenica Therapeutics Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	0.52%	AU$50.00K ≈ $35.38K	AU$9.54 Million ≈ $6.75 Million	--

pp = percentage points

About Argenica Therapeutics Ltd

AU:AGN Australia Biotechnology

Market Cap

$10.00 Million

AU$14.13 Million AUD

Market Cap Rank

#27049 Global

#1319 in Australia

Share Price

AU$0.11

Change (1 day)

+0.00%

52-Week Range

AU$0.11 - AU$0.76

All Time High

AU$0.99